Selective Inhibition of Bruton’s Tyrosine Kinase by a Designed Covalent Ligand Leads to Potent Therapeutic Efficacy in Blood Cancers Relative to Clinically Used Inhibitors

Bárbara B. Sousa(University of Lisbon), Gonçalo J. L. Bernardes(University of Lisbon)
ACS Pharmacology & Translational Science
November 2, 2022
Cited by 9


Related Papers